

REMARKS

Claims 54-57, 59 are pending in the application. Claim 54 has been amended. Newly added Claim 59 recites the free base compound of Claim 54.


Claims 54-58 have been rejected under 35 USC 112, first paragraph, in as much as it is the Office's position that the specification is not enabling for solvates. In view of the amendment to Claim 54 this rejection of the claims is moot.

Claims 57 and 58 have been rejected under 35 USC 112, first paragraph, as failing to comply with the enablement requirement with respect to "neurological diseases". In view of the cancellation of Claim 58 this rejection of the claim is believed to be moot. Claim 57 does not include the above-identified phrase and should be unaffected by this rejection.

Accordingly, it is respectfully requested that all rejections of the claims be reconsidered and withdrawn and that the application as amended be allowed.

The Commissioner is hereby authorized to charge any fees required or credit any overpayment to Deposit Account No. 07-1392.

Respectfully submitted,



Bonnie L. Deppenbrock
Attorney for Applicant
Registration No. 28,209

Date: 6/27/08
GlaxoSmithKline
Corporate Intellectual Property
Five Moore Drive
P.O. Box 13398
Research Triangle Park, NC 27709-3398
Phone: 919-483-1577
Facsimile: 919-483-7988